The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The cost of treatment-related adverse events in metastatic breast cancer therapy: Taxanes versus capecitabine.
Ryan N Hansen
No relevant relationships to disclose
Melissa G. Brammer
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Roche
Scott David Ramsey
Consultant or Advisory Role - Genentech
Deepa Lalla
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Sara A. Hurvitz
Consultant or Advisory Role - Genentech (U)
Sean D Sullivan
Research Funding - Genentech/Roche